Mercado cerrado
Nuvalent/NUVL
13:30
15:10
16:45
18:25
20:00
1D1S1MAHF1A5Y
Acerca de Nuvalent
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Símbolo
NUVL
Sector
Cotiza en
Industria
Biotecnología
Sede central
Empleados
115
Página web
Métricas de Nuvalent
BásicoAvanzado
5516 M$
Capitalización
-
PER
-2,80 $
BPA
1.28
Beta
-
Dividendos
Precio y volumen
Capitalización
5516 M$
Beta
1.28
Solvencia financiera
Ratio de solvencia
17,445
Test ácido
17,229
Eficacia de la gestión
Rendimiento de los activos (TTM)
-22,71 %
Rentabilidad de los fondos propios (TTM)
-32,81 %
Valoración
Ratio precio-valor contable
8,62
Ratio precio-valor contable neto (TTM)
8,62
Ratio precio-flujo de caja libre (TTM)
-40,477
Crecimiento
Variación del beneficio por acción (TTM)
50,71 %
Crecimiento de los beneficios por acción en 3 años (CAGR)
-32,48 %
Qué piensan los analistas de Nuvalent
Valoración de los Analistas
Calificaciones de analistas (comprar, conservar, vender) para la acción Nuvalent.
Rendimiento financiero de Nuvalent
Cuenta de resultados
Ingresos y gastos
TrimestralAnual
Q3 24
Crecimiento intertrimestral
Ingresos
37 mil M$
-39,75 %
Beneficios
45 mil M$
107,52 %
Margen de beneficio
37,65 %
6,78 %
Rentabilidad de Nuvalent
Beneficios por acción (BPA)
Rentabilidad de la empresa
TrimestralAnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Real
3,69 $
2,85 $
2,45 $
2,42 $
-
Previsto
3,55 $
2,61 $
2,05 $
2,31 $
3,94 $
Sorpresa
3,94 %
9,20 %
19,51 %
4,63 %
-
Noticias de Nuvalent
TodosArtículosVídeos
![Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fw%2Fl%2Fconf11-2615205.jpg&w=3840&q=75)
Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
PRNewsWire·hace 3 días
![Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fi%2Fi%2Fpress4-2576397.jpg&w=3840&q=75)
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
PRNewsWire·hace 3 semanas
![Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fg%2Fy%2Fpress5-2536079.jpg&w=3840&q=75)
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
PRNewsWire·hace 1 mes
Los datos expuestos son meramente indicativos y no se garantiza que sean exactos o completos. El precio de ejecución real puede variar. Rentabilidades pasadas no son indicativas de resultados futuros. Tu rentabilidad puede verse afectada por las fluctuaciones monetarias y las comisiones y gastos aplicables. Capital en riesgo.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.